Democritus University of Thrace (DUTH)
Prostate cancer, radiotherapy and immune response
Abstract
dc:descriptionBackground: Prostate cancer constitutes the second most common malignancy in men. Radical prostatectomy and radiotherapy offer high cure rates in the early stages of the disease. Their efficacy is, however, limited in locally advanced and metastatic disease. Despite the development of targeted therapies, there has been no significant progress in prostate cancer that promises better outcomes and improved prognosis. The role of immunotherapy in prostate cancer is currently under investigation. One of the best studied immune escape pathways exploited by cancer cells is the PD-L1/PD-1 immune checkpoint pathway, which the major target we investigated in this PhD thesis. At the same time, we aimed to study the effect of different radiation therapy regimens on the Type I Interferon (IFN) immune response, a pathway with a prominent role in the activation of tumor-targeted immune responses. Finally, we focused on the effects of radiotherapy in the systemic immune response of patients with prostate cancer undergoing radiotherapy with localized or extended fields. Methodology: For this purpose, we focused on tumor microenvironment conditions that could be involved in the overxpression of PD-L1 molecule in prostate cancer. We studied immunohistochemically the expression of PD-L1 in 66 prostate cancer patients, in parallel with the expression of hypoxia and/or acidosis related markers (inducible hypoxia factor HIF1α, and lactate dehydrogenase LDHA). At the same time, the presence and density of tumour-infiltrating lymphocytes and macrophages in the tumour area was assessed. Subsequently, in vitro studies were performed on the DU145 and PC3 hormone independent prostate cancer cell lines, and the 22Rv1 hormone dependent cell lines. We assessed how hypoxia, acidosis, radiation and the interactions of tumor cells with lymphocytes are involved in the induction of PD-L1 molecule in cancer cells. Furthermore, we studied the effect of different radiation fractions on the induction of the Type I Interferon (IFN) pathway, by exposing the three prostate cancer cell lines with two different radiation fractions (3 daily fractions of 8Gy versus a single fraction of 20Gy). Finally, to study the radiation-induced systemic immune response in prostate cancer patients, we examined three groups of patients who underwent different radiation treatment plans; the patients who underwent localized field radical radiotherapy in the prostate region, patients who received extended field irrradiation that included the pelvic lymph nodes, and patients who underwent post-operative radiotherapy due to a biochemical recurrence, again treated with extended irrradiation fields. Blood samples were taken at the beginning and at the end of the treatments, and peripheral blood mononuclear cells (PBMCs) were isolated from the patients that were subsequently used for the analysis of immunological biomarkers (CD4, CD8, CD25, FOXP3) with Flow Cytometry.Results: The immunohistochemical study, showed a direct correlation of PD-L1 expression by tumor cells with tumor-infiltrating lymphocyte and macrophage density (p<0.05), as well as with the overexpression of HIF1α transcription factor and LDH5 protein (p<0.05). At the same time, an inversely proportional correlation was shown between the density of tumor-infiltrating lymphocytes and macrophages and the expression of HIF1α (p=0.02), suggesting a role of hypoxia in defining immunologically cold prosate carcinomas. In in vitro experiments, exposure of prostate cancer cell lines to hypoxia led to a strong induction of the PD-L1 expression, both at the transcriptional and translational level, in a manner directly dependent on the function of the HIF1α factor (p< 0.001). Although irradiation per se did not induce PD-L1 protein expression, exposure of cell lines to culture medium (CM) isolated from PBMCs, induced PD-L1 independently of HIF1α. These findings were strongly supported by further in vitro experiements by exposing the above cell lines to Interferon-γ (p < 0.001). This pointed to a distinct pathway involved in PD-L1 regulation, independent of hypoxia. In contrast to PD-L1, irradiation experiments of prostate cancer cell lines confirmed a strong induction of the Type I Interferon pathway, as all irradiated cell lines exhibited enhanced expression of IFN-induced genes, with this finding being even more pronounced for IFI6v2 and IFI44 genes. Especially fro the PC3 cell lines, a strong up-regulation of the MX1 and MX2 genes was recorded. These results, were independent of the expression of IFNβ, cGAS or TREX1 levels for all cell lines. Analysis of immunological biomarkers in PBMCs from prostate cancer patients undergoing radiotherapy showed a direct effect on systemic immune response. Localized fields sparing tumor draining lymph nodes showed a strong induction of CD8+ T-cells and a reduction of the CD4/CD8 ratio. Irradiation of TDLNs had an inverse effect.Discussion: It is concluded that PD-L1 is inducible in the prostate cancer microenvironment by at least two distinct pathways; one involving hypoxia and HIF1α activation and, another, hypoxia-independent pathway mediated by tumor infiltrating lymphocytes and cytokines release, like IFNγ. Thus, we postulated that specific subgroups of prostate cancer patients could benefit from anti-PDL1/PD-1 immunotherapy alone, while others characterized by up-regulated ΗΙF-pathway may demand concomitant targeting of hypoxia in order to substantiate the benefits from immunotherapy. The direct effect of radiotherapy to induce the type I IFN response and also to activate CD8+ T-cell responses show that RT does indeed trigger a radio-vaccination response, which, however, may be minimized under the irradiation of tumor draining lymph nodes. Further studies are demanded to establish reliable biomarkers to guide anti-PD-L1/PD-1 immunotherapy based on micronevironmental conditions and the intratumoral immune response. Protection of the immune system during extended field radiotherapy emerges also as an important quest with clinical implications.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Xanthopoulou, Erasmia
- Ξανθοπούλου, Ερασμία
Subjects
dc:subject × 30- Καρκίνος του προστάτη
- Ακτινοθεραπεία
- Μονοπάτι PD-1/PD-L1
- Μικροπεριβάλλον όγκου
- Υποξία
- HIF1α
- IFNγ
- Μονοπάτι ιντερφερόνης τύπου Ι
- Γονίδια επαγόμενα από ιντερφερόνη
- Prostate cancer
- Radiotherapy
- PD-1/PD-L1 Pathway
- Tumor microenvironment
- Hypoxia
- Type-I Interferon Pathway
- Interferon stimulated genes
- Βιολογία
- Φυσικές Επιστήμες
- Βιολογία, άλλοι τομείς
- Βιολογία, διεπιστημονική προσέγγιση
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ογκολογία
- Biological Sciences
- Natural Sciences
- Biology, miscellaneous
- Biology, interdisciplinary
- Clinical Medicine
- Medical and Health Sciences
- Oncology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54223